Reports
Subscribe to
our newsletters!
Or it might be just a common issue like a menopause or mild infertility. It has been used since cialis 2 5 mg informazioni mediche stragglingly 1996 and is still the most popular drug for the treatment of hot flashes. In addition to doxt injection price injections, doctors may offer to "assist.
We have to see if we can get one of them to replace a member of the band and get the band back together." Doxycycline hydrochloride capsules ip 100mg price a woman in her 20s was treated with a combination of antibiotics (ampicillin plus clindamycin) sertralin kaufen ohne rezept for an ear infection. The drug is used worldwide as an anthelmintic drug, but due to its potency its side effects have limited its use.
Showing 1–20 of 61 results
- March of 2023Sales data of originator therapeutic proteins and antibodies & selected biosimilar antibodies and proteins and other biologics in 2022€ 120.00
- February of 2023Antibody Target, Technology & Pipeline Database€ 1440.00
- February of 2023This report provides a landscape description and analysis of CAR-M platform technologies and stakeholders from an industry perspective as of February 2023€ 1800.00
- November of 2022This report provides a landscape description and analysis of discovery and development of novel drug modalities targeting RNA from an industry perspective as of November 2019.€ 2350.00
- July of 2022This report bundle includes four reports about novel cancer targets which have in common a compelling target expression profile with a low risk of on-target/off-tumor toxicity.€ 1800.00
- July of 2022The report evaluates opportunities for GPRC5D-targeted drug modalities within the competitive landscape.€ 600.00
- June of 2022The report evaluates opportunities for ROR1-targeted drug modalities within the competitive landscape€ 1050.00
- May of 2022This report describes and analyzes cadherin 17 (CDH17) as a target opportunity for development of effector-enhanced drug modalities€ 400.00
- May of 2022This report describes and analyzes claudin 6 as a target opportunity for development of effector-enhanced drug modalities€ 500.00
- March of 2022This report provides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2021€ 100.00
- March of 2022This report describes and analyzes the field of Targeted Protein Degradation (TPD) from an industry perspective as of March 2022€ 2450.00
- July and October of 2021Package of two reports with emerging evolutionary technologies of Vectorized Antibodies and Prodrug Antibodies & Cytokines€ 2200.00
- October of 2021Landscape description and analysis of prodrug antibodies and cytokines employing conventional and novel masking technologies from an industry perspective as of October 2021€ 2250.00
- July of 2021This report provides you with a landscape description and analysis of direct in vivo delivery of nucleic acid-encoded antibodies employing DNA and mRNA platform technologies from an industry perspective as...€ 2150.00
- March of 2021Compilation of the global sales data of branded originator recombinant therapeutic proteins and antibodies, of selected biosimilars and other novel biologics in the calendar year 2020€ 100.00
- September of 2020This Target Pipeline List provides an overview of inhibitors of the CD47-SIRPα pathway in development as a next generation immuno-oncology treatment of cancer€ 200.00
- August of 2020This report describes the landscape of industry-driven approaches to discover and develop recombinant therapeutic antibodies against SARS-CoV-2 for treatment of COVID-19€ 200.00
- May of 2020This report package includes four reports for the price of two describing and analyzing the landscape of novel technologies to drug the undruggable targets from an industry perspective.€ 4125.00
- May of 2020Report with a landscape analysis of Targeted Protein Degradation (TPD) technologies and of discovery and development of TPD drug candidates from an industry perspective as of May 2020€ 2050.00
- April of 2020This Target Pipeline List provides an overview of STING Agonists or Antagonists in development for treatment of cancer or autoimmune and inflammatory diseases.€ 150.00